Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
Protagenic Therapeutics, Inc. (PTIX)
US:NASDAQ Investor Relations:
protagenic.com/investors
Company Research
Source: GlobeNewswire
NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that upon reviewing its investigational new drug (IND) application filed on June 29th, the U.S. Food and Drug Administration (FDA) has requested that Protagenic provide clinical sites with ready-to-inject clinical vials rather than providing site pharmacies with drug substance to be formulated locally. Implementing this FDA guidance will have the added benefit of Protagenic’s control of the formulation of the final drug product. Protagenic is immediately implementing this required change. As a result of this development, the company expects to refile its IND and commence patient enrollment in the 4th quarter of 2021. About Protagenic Therapeutics, Inc. Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is a pre-clinical biopharmaceutical company endeavoring to develop first-in-c
Show less
Read more
Impact Snapshot
Event Time:
PTIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTIX alerts
High impacting Protagenic Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTIX
News
- Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit [Yahoo! Finance]Yahoo! Finance
- Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston SummitAccesswire
- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results [Yahoo! Finance]Yahoo! Finance
- Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 ResultsAccesswire
PTIX
Sec Filings
- 4/24/24 - Form 10-K/A
- 4/1/24 - Form 4
- 4/1/24 - Form 10-K
- PTIX's page on the SEC website